Caribou Biosciences (CRBU)’s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear Street

Caribou Biosciences, Inc. (NASDAQ:CRBU) is included in our list of the 7 most volatile stocks under $5 for day trading.

A dose bottle of the medication is in the medical tech’s hand

On February 2, 2026, Clear Street began covering Caribou Biosciences, Inc. (NASDAQ:CRBU) with a ‘Buy’ rating and a $13 price target. The firm’s bullish stance was attributed to the company’s off-the-shelf allogeneic CAR-T program, which was described as the primary value generator. The investment bank projected 2040 peak sales of $992 million with a 30% chance of success for the lead candidate, vispa-cel. Caribou is preparing to begin a registrational Phase 3 trial in second-line or later large B-cell lymphoma. Additionally, with a 20% chance of success, Clear Street forecasts that CB-011 may reach $734 million in peak 2040 sales, highlighting both clinical risk and upside potential.

On January 6, 2026, BofA cited a wider reset in U.S. biopharma valuations, cutting its price target on Caribou Biosciences, Inc. (NASDAQ:CRBU) from $8 to $6 while keeping a ‘Buy’ rating. Although durability remains the main point of contention for investors, the investment firm argued that better access to capital, M&A activity, and encouraging data catalysts indicate a biotech turnaround.

Caribou Biosciences, Inc. (NASDAQ:CRBU) focuses on advancing an internal oncology pipeline and supporting broader therapeutic and biotech research uses by leveraging CRISPR genome-editing technology to develop off-the-shelf CAR-T and CAR-NK cell treatments.

READ NEXT: What Are the Best Stocks to Buy Right Now? and 10 Stocks Under $1 That Will Explode.

Disclosure: None.